The anticoagulant and hemorrhagic effects of DHG, a new depolymerized holothurian glycosaminoglycan, on experimental hemodialysis in dogs.
We studied the use of depolymerized holothurian glycosaminoglycan (DHG) as an anticoagulant in experimental beagle-dog hemodialysis using a hollow-fiber dialyzer compared to that using unfractionated heparin (UFH), low-molecular-weight heparin (LMWH), and nafamostat mesilate (FUT). Effectiveness was based on 5 h hemodialysis and no marked clot deposition in the extracorporeal circuit. At effective doses, UFH and LMWH significantly prolonged template bleeding time, in sharp contrast to FUT and DHG, which scarcely prolonged bleeding time during hemodialysis. DHG prolonged activated partial thromboplastin time (APTT) about 6 times that of normal plasma and prolonged thrombin clotting time (TCT) markedly; FUT showed marked APTT prolongation but hardly prolonged TCT in the hemodialysis circuit at the effective dose. The anticoagulant profile of DHG thus differs completely from that of FUT. These results suggest that DHG may be useful as anticoagulant for hemodialysis with low hemorrhagic risk.
Minamiguchi
K
K
Taiho Pharmaceutical Co., Ltd., Tokushima, Japan.
Kitazato
K T
KT
Sasaki
E
E
Nagase
H
H
Kitazato
K
K
D000818:Animals; D000925:Anticoagulants / Q000008:administration & dosage*; D004285:Dogs; D006025:Glycosaminoglycans / Q000008:administration & dosage*; D006493:Heparin / Q000008:administration & dosage; D006495:Heparin, Low-Molecular-Weight / Q000008:administration & dosage; D006435:Renal Dialysis
D000925:Anticoagulants; D006025:Glycosaminoglycans; D006495:Heparin, Low-Molecular-Weight; D006493:Heparin